The Washington University Office of Sponsored Research Services Division has been awarded a $102,495 federal Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). This 2-year grant will fund research to investigate how a combination of an OX40 agonist and PD-1 inhibitor, used as an emerging immune checkpoint therapy, impacts the cardiac immune landscape and promotes myocardial vulnerability. The principal investigator will leverage advanced techniques like spectral flow cytometry, single-cell sequencing, and computational biology to deeply understand the mechanisms by which this combination therapy reshapes the cardiac T-cell population and modulates monocyte recruitment and differentiation. The overarching goal is to uncover mechanism-based therapeutic targets to prevent or treat the adverse cardiac events that can occur with this type of combined immunotherapy approach. This award supports the principal investigator's career development towards becoming an independent investigator in the field of cardio-oncology.
Generated 3/18/25, 4:13 AM